---
title: "ML‑Enabled Multiscale QSP–PBPK Platform to Support Development of mRNA Therapeutics"
id: "medrxiv-16-towards-a-ml-powered-multiscale-computational-platform-based-on-qsp-and-pbpk"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-16-towards-a-ml-powered-multiscale-computational-platform-based-on-qsp-and-pbpk"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.25.26361215v1?rss=1"
published_at: "2026-08-28T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# ML‑Enabled Multiscale QSP–PBPK Platform to Support Development of mRNA Therapeutics
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-16-towards-a-ml-powered-multiscale-computational-platform-based-on-qsp-and-pbpk
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.25.26361215v1?rss=1)
- **Published At:** 2026-08-28T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The authors describe a modular, multiscale computational platform designed to support development of **mRNA-based therapeutics** by integrating mechanistic models across pharmacological scales. - The platform couples a **Quantitative Systems Pharmacology (QSP)** model that represents the immunological cascade from antigen expression in antigen-presenting cells to B cell activation and circulating antibody production. - It also includes a **Physiologically Based Pharmacokinetic (PBPK)** model that tracks whole-body disposition of mRNA-encoded therapeutic antibodies and incorporates a molecular layer for lipid nanoparticle (LNP) uptake, endosomal mRNA escape, and intracellular translation. - A machine learning pipeline links in vitro transcribed (IVT) mRNA nucleotide sequences directly to kinetic parameters, enabling product-specific simulations. - The integrated approach is presented as a step toward a quantitative pharmacological framework that accounts for the tri-component nature of mRNA therapies: the **LNP**, the **mRNA**, and the expressed **protein**. - The authors propose the platform as a practical tool for model-informed design and development of mRNA therapeutics beyond infectious disease vaccines. - All data used in the study were drawn from publicly available human sources cited in the manuscript; the authors report no competing interests and state that relevant ethical guidelines were followed. - The preprint was posted on medRxiv on August 28, 2026; the manuscript and all produced data are contained in the preprint.
## Clinical Analysis & Structured Key Points
Towards a ML-powered Multiscale Computational Platform Based on QSP and PBPK Modeling to Support the Development of mRNA-based Therapies | medRxiv Skip to main content Towards a ML-powered Multiscale Computational Platform Based on QSP and PBPK Modeling to Support the Development of mRNA-based Therapies View ORCID Profile Elisa Pettinà , Frederick Abi Chahine , View ORCID Profile Elio Campanile , View ORCID Profile Stefano Giampiccolo , View ORCID Profile Luca Marchetti doi: https://doi.org/10.64898/2026.08.25.26361215 Elisa Pettinà 1 University of Trento; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Elisa Pettinà Frederick Abi Chahine 1 University of Trento; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Elio Campanile 1 University of Trento; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Elio Campanile Stefano Giampiccolo 2 Fondazione COSBI Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Stefano Giampiccolo Luca Marchetti 1 University of Trento; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Luca Marchetti For correspondence: marchetti{at}cosbi.eu Abstract Info/History Metrics Data/Code Preview PDF Abstract mRNA-based therapeutics have emerged as a transformative class of medicines, yet their translation beyond infectious disease vaccines remains challenged by the absence of an integrated pharmacological framework accounting for the tri-component nature of these therapies - the lipid nanoparticle, the mRNA, and the expressed protein. Here, we present a modular, multiscale computational platform integrating two complementary mechanistic models covering the full pharmacological cascade of mRNA-based immunotherapies. The first is a Quantitative Systems Pharmacology (QSP) model describing the immunological response to mRNA vaccines, from antigen expression in antigen-presenting cells through B cell activation and circulating antibody production. The second is a Physiologically Based Pharmacokinetic (PBPK) model tracking whole-body disposition of mRNA-encoded therapeutic antibodies, incorporating a molecular layer resolving LNP uptake, endosomal mRNA escape, and intracellular translation. Both models are informed by a machine learning pipeline that maps IVT-mRNA nucleotide sequences directly onto kinetic parameters, enabling product-specific model simulations. We propose this platform as a step toward the quantitative pharmacological framework that mRNA therapeutics currently lack, and as a practical tool for model-informed design and development of this therapeutic class. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study used exclusively publicly available human data obtained from the scientific literature. All original sources have been appropriately cited and are included in the reference list of the manuscript. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present work are contained in the manuscript. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted August 28, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Towards a ML-powered Multiscale Computational Platform Based on QSP and PBPK Modeling to Support the Development of mRNA-based Therapies Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Towards a ML-powered Multiscale Computational Platform Based on QSP and PBPK Modeling to Support the Development of mRNA-based Therapies Elisa Pettinà , Frederick Abi Chahine , Elio Campanile , Stefano Giampiccolo , Luca Marchetti medRxiv 2026.08.25.26361215; doi: https://doi.org/10.64898/2026.08.25.26361215 Share This Article: Copy Citation Tools Towards a ML-powered Multiscale Computational Platform Based on QSP and PBPK Modeling to Support the Development of mRNA-based Therapies Elisa Pettinà , Frederick Abi Chahine , Elio Campanile , Stefano Giampiccolo , Luca Marchetti medRxiv 2026.08.25.26361215; doi: https://doi.org/10.64898/2026.08.25.26361215 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Pharmacology and Therapeutics Subject Areas All Articles Addiction Medicine (612) Allergy and Immunology (893) Anesthesia (325) Cardiovascular Medicine (4754) Dentistry and Oral Medicine (474) Dermatology (406) Emergency Medicine (640) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1610) Epidemiology (15808) Forensic Medicine (32) Gastroenterology (1194) Genetic and Genomic Medicine (6971) Geriatric Medicine (727) Health Economics (1051) Health Informatics (4961) Health Policy (1422) Health Systems and Quality Improvement (1731) Hematology (578) HIV/AIDS (1330) Infectious Diseases (except HIV/AIDS) (16230) Intensive Care and Critical Care Medicine (1158) Medical Education (661) Medical Ethics (150) Nephrology (718) Neurology (7165) Nursing (362) Nutrition (1072) Obstetrics and Gynecology (1226) Occupational and Environmental Health (999) Oncology (3563) Ophthalmology (1032) Orthopedics (392) Otolaryngology (445) Pain Medicine (464) Palliative Medicine (139) Pathology (702) Pediatrics (1771) Pharmacology and Therapeutics (731) Primary Care Research (758) Psychiatry and Clinical Psychology (5816) Public and Global Health (9666) Radiology and Imaging (2373) Rehabilitation Medicine and Physical Therapy (1428) Respiratory Medicine (1238) Rheumatology (632) Sexual and Reproductive Health (762) Sports Medicine (572) Surgery (763) Toxicology (106) Transplantation (301) Urology (285)
## Related Clinical Research

- [Methylmalonate Overload and Diabetic Heart Damage Despite Glycemic Control — Study Overview](https://medichelpline.com/clinical-feed/pubmed-42522575.md) (DOI: 10.1161/CIRCRESAHA.125.327192)
- [Spatial patterns and economic burden of comorbidities in hospitalised pulmonary tuberculosis patie](https://medichelpline.com/clinical-feed/pubmed-42663079.md) (DOI: 10.7189/jogh.16.04284)
- [Cassidy report faults FDA oversight of mifepristone manufacturers](https://medichelpline.com/clinical-feed/stat-news-5-stat-cassidy-criticizes-fda-oversight-of-abortion-pill-manufacturers-in-new.md)
- [BINSA bill could protect U.S. biotech — but a loophole may enable ‘Eurowashing’](https://medichelpline.com/clinical-feed/stat-news-4-opinion-stat-a-bill-is-supposed-to-protect-u-s-biotech-from-chinese-competition.md)
- [High‑alert medicines in Sri Lanka: list development and pilot error‑prevention strategies](https://medichelpline.com/clinical-feed/medrxiv-7-development-of-a-high-alert-medicines-list-and-pilot-testing-of-error.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.